Our Chief Strategy Officer and Head of Drug Discovery, Stacie Calad-Thomson, PhD, is a featured author in the January edition of European Biopharmaceutical Review. To read the full article, “Phenomics: What It Is and Why It Is the Future of Drug Discovery,” go here.
NEWS: European Biopharmaceutical Review: Op-Ed on Phenomics, the Future of Drug Discovery
Previous
Previous
Sema4 and BioSymetrics Partner on Data-Driven Drug Discovery to Advance Precision Medicine
Next
Next

